MVMari Vähä-Mäkilä

Mari Vähä-Mäkilä

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mari Vähä-Mäkilä has a total of 297 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Umbilical cord blood DNA methylation in children who later develop type 1 diabetes

    by Essi Laajala, Ubaid Ullah Kalim, Toni Grönroos, Omid Rasool, Viivi Halla-Aho, Mikko Konki, Roosa Kattelus, Juha Mykkänen, Mirja Nurmio, Mari Vähä-Mäkilä, et al.

    Aims/hypothesis: Distinct DNA methylation patterns have recently been observed to precede type 1 diabetes in whole blood collected from young children. Our aim was to determine whether perinatal DNA methylation is associated with later progression to type 1 diabetes. Methods: Reduced representation bisulphite sequencing (RRBS) analysis was performed on umbilical cord blood samples collected within the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study. Children later diagnosed with type 1 diabetes and/or who tested positive for multiple islet autoantibodies (n = 43) were compared with control individuals (n = 79) who remained autoantibody-negative throughout the DIPP follow-up until 15 years of age. Potential confounding factors related to the pregnancy and the mother were included in the analysis. Results: No differences in the umbilical cord blood methylation patterns were observed between the cases and controls at a false discovery rate <0.05. Conclusions/interpretation: Based on our results, differences between children who progress to type 1 diabetes and those who remain healthy throughout childhood are not yet present in the perinatal DNA methylome. However, we cannot exclude the possibility that such differences would be found in a larger dataset. Graphical


  • Open Access

    Serum 25-Hydroxyvitamin D Concentrations at Birth in Children Screened for HLA-DQB1 Conferred Risk for Type 1 Diabetes

    by Marjaana Mäkinen, Eliisa Löyttyniemi, Maarit Koskinen, Mari Vähä-Mäkilä, Heli Siljander, Mirja Nurmio, Juha Mykkänen, Suvi M Virtanen, Olli Simell, Heikki Hyöty, et al.

    Context Vitamin D has several effects on the immune system that might be of relevance for the pathogenesis of type 1 diabetes (T1D). Objective To evaluate whether umbilical cord serum concentrations of 25-hydroxy-vitamin D (25[OH]D) differ in children developing either islet autoimmunity (IA) or overt T1D during childhood and adolescence. Design Umbilical cord serum samples from 764 children born 1994-2004 with HLA-DQB1 conferred risk for type 1 diabetes (T1D) participating in the Type 1 Diabetes Prediction and Prevention Study (DIPP) were analyzed for 25(OH)D using an enzyme immunoassay. Setting DIPP clinics in Turku, Oulu, and Tampere University Hospitals, Finland. The participants comprised 250 case children who developed T1D diabetes at a median age of 6.7 years (interquartile range [IQR] 4.0-10.1 years) and 132 additional case children who developed IA, i.e. positivity for multiple islet autoantibodies. Cases were matched for date of birth, sex and area of birth with 382 control children who remained autoantibody negative. The median duration of follow-up was 9.8 years (IQR 5.7-13.1 years). Main Outcome Measure The median 25(OH)D concentrations Results The median 25(OH)D concentration in cord serum was low (31.1 nmol/L [IQR 24.0-41.8]; 88% < 50 nmol/L), but not statistically different between children who developed T1D or IA and their control groups (P=0.70). The levels were associated mainly with geographical location, year and month of birth, age of the mother and maternal intake of vitamin D during pregnancy. Conclusions The 25(OH)D concentrations at birth are not associated with the development of T1D during childhood.


  • Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes

    by Amir-Babak Sioofy-Khojine, Jussi Lehtonen, Noora Nurminen, Olli H. Laitinen, Sami Oikarinen, Heini Huhtala, Outi Pakkanen, Tanja Ruokoranta, Minna M. Hankaniemi, Jorma Toppari, et al.

    Islet autoimmunity usually starts with the appearance of autoantibodies against either insulin (IAA) or GAD65 (GADA). This categorises children with preclinical type 1 diabetes into two immune phenotypes, which differ in their genetic background and may have different aetiology. The aim was to study whether Coxsackievirus group B (CVB) infections, which have been linked to the initiation of islet autoimmunity, are associated with either of these two phenotypes in children with HLA-conferred susceptibility to type 1 diabetes.


  • Open Access

    Correction: Corrigendum: A Comparison of Rule-based Analysis with Regression Methods in Understanding the Risk Factors for Study Withdrawal in a Pediatric Study

    by Mona Haghighi, Suzanne Bennett Johnson, Xiaoning Qian, Kristian F. Lynch, Kendra Vehik, Shuai Huang, The TEDDY Study Group, Marian Rewers, Kimberly Bautista, Judith Baxter, et al.

    Scientific Reports 6: Article number: 30828; published online: 26 August 2016; updated: 02 May 2017 In the original version of this Article, the author list for the “TEDDY Study Group” was incomplete. This has now been corrected in the PDF and HTML versions of this Article.


  • Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life

    by Igor C. Borges, Dafne C. Andrade, Maria Regina A. Cardoso, Jorma Toppari, Mari Vähä-Mäkilä, Jorma Ilonen, Mikael Knip, Heikki Hyöty, Riitta Veijola, Olli Simell, et al.

    Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies ( r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.


  • Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI)

    by Johanna Kurko, Maaria Tringham, Laura Tanner, Kirsti Näntö-Salonen, Mari Vähä-Mäkilä, Heli Nygren, Päivi Pöhö, Niina Lietzen, Ismo Mattila, Anu Olkku, et al.


  • Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort

    by Carin Andrén Aronsson, Hye-Seung Lee, Sibylle Koletzko, Ulla Uusitalo, Jimin Yang, Suvi M. Virtanen, Edwin Liu, Åke Lernmark, Jill M. Norris, Daniel Agardh, et al.


  • Open Access

    Reduced β-cell function in early preclinical type 1 diabetes

    by Maarit K Koskinen, Olli Helminen, Jaakko Matomäki, Susanna Aspholm, Juha Mykkänen, Marjaana Mäkinen, Ville Simell, Mari Vähä-Mäkilä, Tuula Simell, Jorma Ilonen, et al.

    Objective: We aimed to characterize insulin responses to i.v. glucose during the preclinical period of type 1 diabetes starting from the emergence of islet autoimmunity.Design and methods: A large population-based cohort of children with HLA-conferred susceptibility to type 1 diabetes was observed from birth. During regular follow-up visits islet autoantibodies were analysed. We compared markers of glucose metabolism in sequential intravenous glucose tolerance tests between 210 children who were positive for multiple (≥2) islet autoantibodies and progressed to type 1 diabetes (progressors) and 192 children testing positive for classical islet-cell antibodies only and remained healthy (non-progressors).Results: In the progressors, the first phase insulin response (FPIR) was decreased as early as 4–6 years before the diagnosis when compared to the non-progressors (P=0.001). The difference in FPIR between the progressors and non-progressors was significant (PP<0.001; at 2 years: difference 36% (95% CI 17–58%) and at 10 years: difference 186% (95% CI 143–237%)). Insulin sensitivity did not differ between the groups.Conclusions: FPIR is decreased several years before the diagnosis of type 1 diabetes, implying an intrinsic defect in β-cell mass and/or function.


  • Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport

    by Johanna Kurko, Mari Vähä-Mäkilä, Maaria Tringham, Laura Tanner, Sari Paavanen-Huhtala, Maiju Saarinen, Kirsti Näntö-Salonen, Olli Simell, Harri Niinikoski, Juha Mykkänen


  • Serum Proteomes Distinguish Children Developing Type 1 Diabetes in a Cohort With HLA-Conferred Susceptibility

    by Robert Moulder, Santosh D. Bhosale, Timo Erkkilä, Essi Laajala, Jussi Salmi, Elizabeth V. Nguyen, Henna Kallionpää, Juha Mykkänen, Mari Vähä-Mäkilä, Heikki Hyöty, et al.

    We determined longitudinal serum proteomics profiles from children with HLA-conferred diabetes susceptibility to identify changes that could be detected before seroconversion and positivity for disease-associated autoantibodies. Comparisons were made between children who seroconverted and progressed to type 1 diabetes (progressors) and those who remained autoantibody negative, matched by age, sex, sample periodicity, and risk group. The samples represented the prediabetic period and ranged from the age of 3 months to 12 years. After immunoaffinity depletion of the most abundant serum proteins, isobaric tags for relative and absolute quantification were used for sample labeling. Quantitative proteomic profiles were then measured for 13 case-control pairs by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Additionally, a label-free LC-MS/MS approach was used to analyze depleted sera from six case-control pairs. Importantly, differences in abundance of a set of proteins were consistently detected before the appearance of autoantibodies in the progressors. Based on top-scoring pairs analysis, classification of such progressors was observed with a high success rate. Overall, the data provide a reference of temporal changes in the serum proteome in healthy children and children progressing to type 1 diabetes, including new protein candidates, the levels of which change before clinical diagnosis.